Double cortin-like kinase 1 (DCLK1) plays important roles during the epithelial-mesenchymal transition (EMT) process in human colorectal cancer (CRC). However, the role of DCLK1 in regulating the EMT of CRC is still poorly understood. In this study, we report evidence that DCLK1 acts as a potent oncogene to drive its extremely malignant character of EMT in an NFjB-dependent manner in CRC cells. Mechanistic investigations showed that DCLK1 induced the NF-jBp65 subunit expression through the PI3K/Akt/Sp1 axis and activated NF-jBp65 through the PI3K/Akt/IjBa pathway during the EMT of CRC cells. Moreover, we found that silencing the expression of DCLK1 inhibited the invasion and metastasis of CRC cells in vivo. Collectively, our findings identify DCLK1 as a pivotal regulator of an EMT axis in CRC, thus implicating DCLK1 as a potential therapeutic target for CRC metastasis.
Introduction
Colorectal cancer (CRC) is still the third most common cancer in the world, 1 and the overwhelming majority of patients diagnosed with advanced stage are usually accompanied by metastasis. 2, 3 Metastasis in patients with CRC is a major cause of recurrence before radical surgery, and patients with synchronous liver metastasis exhibit a poor 5-year survival rate of only 3.3%. 3 Although the extensive published literature has uncovered several molecular mechanisms that cause the metastasis in CRC, a variety of molecular factors and signal transduction pathways involving tumor metastasis still remain largely elusive. 4 Tumor metastasis is a complicated process influenced by several molecular factors. Epithelial-mesenchymal transition (EMT) has been considered to be a key program associated with the invasion and metastasis of several malignant tumors, including CRC. 4, 5 EMT allows the epithelial cells to disrupt cell-cell adherence, lose their apical-basal polarity and acquire mesenchymal characteristics through cytoskeletal remodeling. 6 During EMT, epithelial cells gradually lose the expression of E-cadherin, which serves as the most important epithelial marker while concomitantly increasing the expression of mesenchymal markers, such as Vimentin and Fibronectin. 7 EMT can be induced through the upregulation of several upstream transcriptional regulators such as SNAIL, ZEB and TWIST. 8, 9 Several signaling molecules and pathways have been demonstrated to be involved in this process.
Double cortin-like kinase 1 (DCLK1, formerly known as DCAMKL1), a member of the protein kinase superfamily and the double cortin family, was initially identified as a critical regulator of neurogenesis and neuronal migration. 10 Recently, DCLK1 has been identified as a tumor stem cell marker in CRC, pancreatic cancer and other cancers. [11] [12] [13] [14] [15] [16] DCLK1 protein is highly expressed in several types of cancers, including CRC, 17 pancreatic cancer, 18 hepatocellular carcinoma (HCC), 19 and renal clear cell carcinoma (RCC). 16 Moreover, recent studies have demonstrated that the DCLK1 gene promoter is hyper methylated in several cancers. [20] [21] [22] [23] Subsequent studies have shown that the DCLK1 gene can encode four different isoforms through alternative promoters and splicing mechanism, and DCLK1 isoform 2, originating from alternate 5 0 (b)-promoter, is highly expressed in human CRC cell lines and patient samples. 24 DCLK1 can promote pluripotency, angiogenesis and EMT through microRNA-dependent mechanisms through the downregulation of several key tumor suppressor microRNAs. Forinstance, DCLK1 can promote pluripotency through the downregulation of the expression of miR-143/145, which can result in an increase in the expression of pluripotency maintenance factors such as NANOG, OCT4, KLF4, SOX2, as well as RREB1 and KRAS.
13 DCLK1 can promote EMT through the downregulation of the expression of miR-200a, thus, increasing the expression of the EMT-related transcription factors ZEB1, ZEB2, SNAIL and SLUG. 13, 18 Although studies have demonstrated that DCLK1 can regulate EMT through microRNAdependent mechanism, it is still unclear whether the underlying mechanism of EMT is regulated by DCLK1.
In this study, we demonstrated that DCLK1 promotes EMT through the NF-jB mediated mechanism in CRC cells. On the one hand, DCLK1 increases the expression of NFjBp65 expression through the PI3K/Akt/Sp1 axis during EMT, and, on the other hand, DCLK1 activates NF-jBp65 through the PI3K/Akt pathway. Taken together, these findings may provide novel insights into the EMT mechanism regulated by DCLK1, and targeting DCLK1 may be a therapeutic option for CRC metastasis.
Materials and Methods

Tissue samples
A total of 20 CRC tissues and their adjacent nontumor tissues were acquired from the Department of Surgery, Secondary Hospital of Tianjin Medical University (Tianjin, China). All the tissues confirmed by pathological analysis were immediately collected, frozen in liquid nitrogen and stored at 2808C.
Cell culture and transfection
HCT116 and SW480 cell lines were cultured in RPMI1640medium (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum (FBS; Gibco, Grand Island, NY), and 1% PS (100 U/ml penicillin, 100 lg/ml streptomycin) at 378C and 5% CO 2 . Cells were transfected with the control, knockdown and overexpressed vectors using Lipofectamine TM 2000 (Thermo Fisher Scientific, Inc.) according to the manufacturer's protocols.
Plasmid construction
DCLK1 gene fragment was amplified from the cDNA of the HCT116 cells and cloned into pcDNA3 vector (Invitrogen). Relatively oligo nucleotides of DCLK1, p65, Sp1 and PIK3R1 were annealed and cloned into pSilencer 2.1-U6 neo vector (Ambion, Austin, TX), generation of their knockdown plasmids. All the primers and oligonucleotides used in this study are listed in Supporting Information Table supplement 1.
Real-time quantitative PCR
Total RNA was isolated using TRIzol reagent (Invitrogen) according to the manufacturer's protocol. Real-time quantitative PCR (RT-qPCR) methods were performed to detect mRNA levels as described previously. 25 The housekeeping gene b-actin was used as an internal reference gene for normalization of the relative expression levels of target genes. The primers used for qPCR are listed in Supporting Information Table supplement 1.
Transwell assays
HCT116 and SW480 cells were seeded into 24-well plates for 16-18 hr, and then the cells were transfected with relative plasmids and the culture was continued for 18-24 hr. Transwell migration and invasion assays were carried out using transwell chamber inserts (8 lm-pore size membranes, Millipore) with Matrigel (for invasion) or without Matrigel (for migration). The procedures were carried out according to the literature as described previously. 26 Briefly, after transfection, CRC cells were seeded into the upper chamber of the insert (6 3 10 4 cells for HCT116 or 8 3 10 4 cells for SW480) in 200 ll of serum-free RPMI 1640 medium, followed by the addition of 600 ll of serum-free RPMI 1640 medium containing 20% FBS into the bottom of the insert. The HCT116 cells were cultured for 36 hr for migration and for 48 hr for invasion, whereas the SW480 cells were allowed to migrate for 48 hr and invade for 72 hr. The migrated or invaded cells were stained with crystal violet and photographed using a microscope.
Western blotting analysis
Western blotting was performed using antibodies against DCLK1 (diluted 1:200), Vimentin (diluted 1:500), GAPDH (diluted 1:2,000), E-cadherin (diluted 1:100), p65 (diluted 1:500), p-p65 S536 (diluted 1:500), p-IjBa S32/36 (diluted 1:100),IjBa (diluted 1:500), ZEB1 (diluted 1:500), TWIST1 (diluted 1:500), Sp1 (diluted 1:500), PIK3R1 (diluted 1:200), Akt (diluted 1:500) and p-Akt S473 (diluted 1:500). DCLK1, Vimentin, E-cadherin, GAPDH, Sp1, PIK3R1 were purchased from Tianjin Saier Biotech (Tianjin, China). H2A.X, ZEB1, TWIST1, IjBa, p65, p-p65 S536 , Akt and p-Akt S473 were purchased from Wanlei bio Company (Shenyang, China). pIjBa S32/36 was purchased from ImmunoWay Biotech Company (United States). Secondary goat anti-rabbit antibody was purchased from Sigma-Aldrich (St Louis, MO). Whole cell lysate and cytoplasmic proteins were normalized with an What's new? A change in tumor cells called "epithelial-mesenchymal transition" (EMT) helps certain types of tumors to metastasize. In this study of colorectal cancer (CRC), the authors found that an enzyme called DCLK1 acts as a potent oncogene to drive EMT, via NF-jBp65 induction. They, then, further identified the molecular pathways involved in this event regulated through PI3K/Akt pathway. Finally, they found that silencing DCLK1 expression could inhibit metastasis of CRC cells in vivo. These results suggest that DCLK1 may offer a potential therapeutic target for metastatic CRC.
internal reference protein GAPDH, while nuclear proteins were normalized with H2A.X. LabWorks Image Acquisition and Analysis Software (UVP, Upland, CA) were performed to quantify the band density.
Immunofluorescent staining
Standard immunofluorescence protocols were performed as previously described. 26 Specific primary antibodies against Dclk1 (anti-rabbit, diluted 1:100) was obtained from Tianjin Saier Biotech (Tianjin, China), and p65 (anti-mouse, diluted 1:200) was obtained from ImmunoWay, United States. Alexa Fluor 594 donkey anti-rabbit IgG and Alexa Fluor 488 donkey anti-mouse IgG were obtained from Invitrogen (United States).
Luciferase reporter assay
CRC cells were transfected with the indicated luciferase reporter constructs and the luciferase activity was measured by Dual luciferase assay system (Promega, Madison WI) according to previously described.
27,28
Immunohistochemical analysis
Standard immunohistochemistry (IHC) protocols were performed with specific antibodies according to previously reported. 29 In vivo metastasis assay Briefly, 1 3 10 6 cells of HCT116 stable cell strains carrying empty vector with control shRNA or shDCLK1 plasmid were injected into the lateral tail vein of 6-week-old female nude mice. After 7 weeks of initial implantation, the mice were euthanized and the lung tissues were isolated for further study. Animal handling and procedures were carried out in accordance with the National Institutes of Health guide for the care and use of Laboratory animals (NIH Publications No. 8023, revised 1978) and were approved by the Tianjin Medical University Institutional Animal Care.
Statistical analysis
For statistical analyses, student's t test was performed using Graph Pad Prism 6, p values < 0.05 were considered statistically significant (*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001). All experiments were performed independently at least three times.
Results
DCLK1 promotes EMT in CRC cells
To investigate the role of DCLK1 in CRC, we first assessed the results of DCLK1 (DCLK1 isoform 2, also termed as DCLK1-S) expression levels by IHC and RT-qPCR methods. The results showed that the expression level of DCLK1 was markedly upregulated in human CRC tissues compared with that in adjacent noncancerous tissues (Figs. 1a and 1b) . Our finding consisted with the recently reported finding that DCLK1-S is highly expressed in human CRC cell lines and patient samples. 24 Then, the results of RT-qPCR and Western blot analysis showed that overexpression of DCLK1 could markedly increase the transcriptional level and protein level of DCLK1 in both HCT116 and SW480 cells (Figs. 1c and 1d and Supporting Information Fig. 1a ). In contrast, the opposite phenomenon was observed in HCT116 and SW480 cells in which DCLK1-knockdown plasmid was stably expressed (Figs. 1c and 1d and Supporting Information Fig. 1a) . The role of DCLK1 in cell migration and invasion in CRC cells was determined by transwell assays, which showed that the overexpression of DCLK1 markedly promoted the cell migration and invasion abilities; whereas, the downregulation of DCLK1 exhibited relatively lower abilities (Figs. 1e and 1f) .
To further investigate the underlying mechanisms of how DCLK1 promotes cell migration and invasion, we detected the expression of critical EMT markers, E-cadherin and Vimentin. RT-qPCR and Western blot analysis revealed that overexpression of DCLK1 led to a reduction of E-cadherin expression, which is an epithelial marker, but it significantly increased the expression of mesenchymal markers such as Vimentin at both the mRNA and protein levels (Figs. 1g and 1h and Supporting Information Figs. 1b and 1c). In contrast, the downregulation of DCLK1 could increase E-cadherin expression but reduce Vimentin expression at both the mRNA and protein levels (Figs. 1g and 1h and Supporting Information Figs. 1b and 1c ). In addition, we also detected upstream transcriptional regulators (ZEB1and TWIST1) of EMT, wherein the results showed that overexpression of DCLK1 increased the expression of ZEB1and TWIST1, which was reduced by the downregulation of DCLK1 at both the mRNA and protein levels (Figs. 1g and 1h and Supporting Information Figs. 1b and 1c) .Taken together, our results indicated that DCLK1 could promote the migration and invasion of CRC cells through the induction of EMT.
DCLK1 promotes EMT through the upregulation of p65 expression
To ourknowledge, the short form of DCLK1 (DCLK1 isoform 2) has been reported to be highly expressed in human CRC tissues, and the high expressors had a markedly worse overall survival compared to that of low expressors. 24 However, in mouse CRC tissues, it has been demonstrated that the long form of DCLK1 (DCLK1 isoform1) was highly expressed. 24 Previous reports have shown that p65 was highly expressed in DCLK1
1 small intestinal epithelial tuft cells of mouse. 30 Increasing evidence havs indicated that the NF-jB subunit p65 playes a central role in the induction of EMT and the promotion of tumor metastasis. 31 To investigate whether p65 is involved in DCLK1-induced EMT, we analyzed the expression level of p65 in both HCT116 and SW480 cells. Our results showed that p65 expression was significantly increased in CRC tissues compared with that in the adjacent noncancerous tissues (Figs. 2a and 2b) , and the expression of p65 showed a positive correlation with the upregulation of DCLK1 mRNA (Fig. 2c) . Overexpression of DCLK1 in CRC cells increased the p65 expression at both the mRNA and protein levels, whereas the mRNA and protein levels of p65 expression were decreased by the knockdown of DCLK1 (Figs. 2d and 2e and Supporting Information Fig. 2a) . To confirm whether DCLK1 promotes EMT through the p65-mediated mechanism, we detected the effect of p65 expression on the DCLK1-induced cell migration and invasion in Figs. 2b and 2c) . These results indicated that DCLK1-induced EMT is dependent on the expression of p65.
DCLK1 upregulates p65 expression by increasing Sp1 expression during EMT
It has been reported that the transcription factor Sp1 is involved in the upregulation of the NF-jB subunit p65 by binding the p65 promoter and increasing the p65 promoter activity. 32, 33 To assess whether Sp1 is required for the upregulation of p65 expression in DCLK1-induced EMT, we first observed that Sp1 expression was highly expressed in CRC tissues (Figs. 3a and 3b) , which also showed a positive correlation with the upregulation of DCLK1 (Fig. 3c) . Sp1 was significantly increased in DCLK1-overexpressed CRC cells, whereas the expression of Sp1 was suppressed by the knockdown of DCLK1 (Figs. 3d and 3e and Supporting Information Fig. 3a) . The knockdown of Sp1 partly rescued DCLK1-induced changes in the EMT phenotype, including the migration and invasion (Figs. 3f and 3g) , and the associated EMT markers (E-cadherin and Vimentin) (Figs. 3h and 3i and Supporting Information Figs. 3b and 3c ). More importantly, the knockdown of Sp1 was able to block the DCLK1-induced upregulation of p65 expression (Figs. 3h and 3i and Supporting Information Figs. 3b and 3c) . Therefore, our results indicated that the induction of EMT and the upregulation of p65 expression by DCLK1 are dependent on Sp1 expression.
DCLK1 upregulates Sp1 expression via the PI3K/Akt pathway
The phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway can increase the transcriptional expression of Sp1, and the PI3K/Akt/Sp1 pathway is also positively involved in several cellular functions. [34] [35] [36] PI3Ks exist as heterodimers containing a unique catalytic subunit (p110a, b or d) along with one of a number of shared regulatory subunits (p85a, p85b or p55d), 37 and the p85a regulatory subunit of PI3K (PIK3R1) is an oncogene involved in the tumorigenesis of human colon cancer and ovarian tumors. 38 To investigate the role of PIK3R1 in DCLK1-induced EMT, we first determined the expression level of PIK3R1 in CRC tissues and normal tissues, and the results showed that PIK3R1 was upregulated in CRC tissues compared with that in the adjacent noncancerous tissues (Figs. 4a and 4b) , which also displayed a positive correlation with the upregulation of DCLK1 (Fig. 4c) . PIK3R1 expression was markedly upregulated in DCLK1-overexpressed CRC cells, whereas the expression of PIK3R1 was reduced by the silencing of DCLK1 (Figs. 4d and 4e and Supporting Information Fig. 4a ). The silencing of PIK3R1 partly blocked DCLK1-induced changes in EMT phenotype (Figs. 4f and 4g) , and associated EMT markers (E-cadherin and Vimentin) (Figs. 4h and 4i and Supporting Information Figs. 4b and 4c) . Moreover, downregulation of PIK3R1 could abrogate the DCLK1-induced upregulation of Sp1 and p65 expression (Figs. 4h and 4i and Supporting Information Figs. 4b and 4c), indicating that blockage of the PI3K/Akt pathway reversed DCLK1-induced EMT.
DCLK1 promotes EMT through the activation of NF-jB signaling
NF-jBp65 performs its function requiring the translocation of thep65 subunit from the cytoplasm to the nucleus. To further investigate the effects of DCLK1 on NF-jB activation, immunofluorescence analysis showed that the nuclear form of p65 was markedly higher in DCLK1-overexpressed CRC cells than that in empty vector-transfected cells, and the reverse results were obtained in DCLK1-downexpressed CRC cells (Fig. 5a) . Furthermore, Western blot analysis demonstrated that DCLK1 could activate p65 expression in CRC cells ( Fig. 5b and Supporting Information Figs. 5a and 5b) . Luciferase reporter assays demonstrated that NF-jB transcriptional activity was significantly higher in stably DCLK1-transfected cells than that in empty vector-transfected cells, and NF-jB transcriptional activity was relatively lower in stably DCLK1-downregulated cells than in empty vectortransfected cells (Fig. 5c ). Taken together, these results indicated that NF-jB signaling pathway was activated in DCLK1-induced EMT.
DCLK1 activates NF-jB through the PI3K/Akt pathway during EMT
Our results have demonstrated that the DCLK1/PI3K/Akt/ Sp1 axis could increase the expression of p65. However, it is known that the PI3K/Akt pathway can also activate NF-jB signaling. 39 Therefore, we hypothesized that DCLK1 activated NF-jB through the PI3K/Akt pathway in CRC cells. To clarify this hypothesis, we first detected the expression levels of PIK3R1, p-Akt, p-IjB and p-p65 in stably DCLK1-overexpressed CRC cells and found that PIK3R1, p-Akt, pIjB, p-p65 and downstream signal molecules were all upregulated in such cells (Supporting Information Figs. 6a and 6b, Fig. 6a and Supporting Information Figs. 7a and 7b ). In addition, PIK3R1, p-Akt, p-IjB, p-p65 and downstream signal molecules were all downregulated while DCLK1 was knocked down in CRC cells (Supporting Information Figs. 6a and 6b, Fig. 6a and Supporting Information Figs. 7a and 7b) . To further validate the involvement of PI3K/Akt in NF-jB activation, we found that the knockdown of PIK3R1 abrogated the expression levels of p-Akt, p-IjB, p-p65 and downstream signal molecules in DCLK1-induced cells (Supporting Information Figs. 6c and 6d, Fig. 6b and Supporting Information Figs. 7c and 7d) . Moreover, in vivo animal metastasis experiments showed that silencing DCLK1 inhibited lung metastasis of CRC cells (Fig. 6c) . Taken together, these results indicated that DCLK1 exactly activates NF-jB through the PI3K/Akt pathway during EMT.
Discussion
DCLK1 is known to be a critical regulator involved in the promotion of pluripotency, angiogenesis and EMT through microRNAdependent mechanisms by downregulating several key tumor suppressor microRNAs. Except for the microRNA-dependent mechanisms, the underlying mechanism of EMT induced by DCLK1 is still unclear.
The current study provides novel insights into how DCLK1 promotes EMT through the NF-jB-mediated mechanism in CRC cells. Due to the fact that p65 was highly 1 small intestinal epithelial tuft cells of mouse, 30 we hypothesized that DCLK1 also promotes the expression of p65 in human CRC. Our results showed that DCLK1 exactly promoted the mRNA and protein levels of p65, which was involved in the DCLK1-induced EMT process. Previous studies have shown that the p65 promoter region contains Sp1 binding sites and the increase of Sp1 expression can increase the p65 promoter activity and upregulate NF-jB subunit p65 expression. 32, 33 To investigate whether Sp1 involving in upregulating p65 expression, we first observed whether Sp1 was regulated by DCLK1. We found that DCLK1 promoted Sp1 expression, subsequently increasing the expression of p65. Knockdown of Sp1 partly rescued the DCLK1-induced changes in the EMT phenotype and the associated EMT markers (E-cadherin and Vimentin).
Given that the PI3K/Akt/Sp1 pathway is positively involved in several cellular functions, [34] [35] [36] we analyzed the role of PI3K/Akt in Sp1 expression during DCLK1-induced EMT. PIK3R1 is the regulatory subunit of PI3Ks and has proven to be an oncogene involved in the tumorigenesis of human colon cancer and ovarian tumors. 38 We observed that PIK3R1 was markedly upregulated in DCLK1-overexpressed CRC cells, and the silencing of PIK3R1 partly blocked the DCLK1-induced changes in the EMT phenotype and the associated EMT markers (E-cadherin and Vimentin). Furthermore, the downregulation of PIK3R1 was able to abrogate the DCLK1-induced upregulation of Sp1 and p65 expression. Accordingly, p65 is involved in the DCLK1-induced EMT through the PI3K/Akt/Sp1 pathway in CRC cells. Although DCLK1 can promote EMT by increasing the expression of p65, the activation of NF-jB has been demonstrated to be a recognized event in the EMT process. 31 Immunofluorescence analysis, Western blot analysis and luciferase reporter assays were performed to demonstrate whether the NF-jB signaling pathway was activated in DCLK1-induced EMT. It is known that the PI3K/Akt pathway not only increases the p65 expression through the upregulation of Sp1 but also activates NF-jB signaling. 39 To clarify whether the PI3K/Akt pathway is also involved in the activation of p65 during the DCLK1-induced EMT process, the downstream molecules of PI3K were detected by Western blotting. The expression levels of p-Akt, p-IjB and p-p65 were all upregulated in stably DCLK1-overexpressed CRC cells, indicating the possible activation of NF-jB by the PI3K/Akt pathway. PIK3R1 is the p85a regulatory subunit of PI3K and has been proven to be an oncogene involved in human tumorigenesis. However, the role of PIK3R1 in NF- jB activation is still unknown. 38 To further validate whether the activation of NF-jB is dependent on the increased expression of PIK3R1 in DCLK1-induced EMT, we observed that the downregulation of PIK3R1 blocked the expression levels of p-Akt, p-IjB and p-p65 in DCLK1-induced cells. Being the important transcription factors and the major regulators in the EMT, ZEB1 and TWIST1 are directly regulated by NF-jB. 40, 41 The expression levels of ZEB1 and TWIST1, as well as their downstream EMT markers E-cadherin and Vimentin, were also regulated by PIK3R1 in DCLK1-induced EMT. Moreover, it has been reported that NF-jB can directly bind the promoter of Vimentin to directly regulate its expression. 42 Taken together, these results indicated that DCLK1 exactly activates NF-jB through the PI3K/Akt pathway during EMT.
In summary, our study demonstrated the involvement of NF-jB in the DCLK1-induced EMT process in CRC cells. DCLK1 can promote EMT through the upregulation of NFjBp65 expression by the PI3K/Akt/Sp1 axis, and NF-jBp65 is also activated through the PI3K/Akt pathway (Fig. 6d) . Our findings may provide a new insight into the DCLK1-mediated EMT mechanism, thus, implicating DCLK1 as a potential therapeutic target for CRC metastasis. 
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